Seung-Won Choi (Seung Won Choi)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 10

Top Venues

Experimental & molecular medicine

Cancer medicine

Nature genetics

Cell death & disease

Samsung Advanced Institute for Health Sciences & Technology (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Samsung Advanced Institute for Health Sciences & Technology

South Korea

PHD

University of Ulsan College of Medicine

South Korea

MSC

Publications

Eunhyeong Lee, Eun-Ah Lee, Eunji Kong, Haemin Chon, Melissa Llaiqui-Condori, Cheon Ho Park, Beom Yong Park, Nu Ri Kang, Jin-San Yoo, Hyun-Soo Lee, Hyung-Seok Kim, Sung-Hong Park, Seung-Won Choi, Dietmar Vestweber, Jeong Ho Lee, Pilhan Kim, Weon Sup Lee, Injune Kim
An agonistic anti-Tie2 antibody suppresses the normal-to-tumor vascular transition in the glioblastoma invasion zone. Experimental & molecular medicine 55 (2) (2023)
Eunhyeong Lee, Eun-Ah Lee, Eunji Kong, Haemin Chon, Melissa Llaiqui-Condori, Cheon Ho Park, Beom Yong Park, Nu Ri Kang, Jin-San Yoo, Hyun-Soo Lee, Hyung-Seok Kim, Sung-Hong Park, Seung-Won Choi, Dietmar Vestweber, Jeong Ho Lee, Pilhan Kim, Weon Sup Lee, Injune Kim
An agonistic anti-Tie2 antibody suppresses the normal-to-tumor vascular transition in the glioblastoma invasion zone. Experimental & molecular medicine 55 (2) (2023)
Eunhyeong Lee, Eun-Ah Lee, Eunji Kong, Haemin Chon, Melissa Llaiqui-Condori, Cheon Ho Park, Beom Yong Park, Nu Ri Kang, Jin-San Yoo, Hyun-Soo Lee, Hyung-Seok Kim, Sung-Hong Park, Seung-Won Choi, Dietmar Vestweber, Jeong Ho Lee, Pilhan Kim, Weon Sup Lee, Injune Kim
An agonistic anti-Tie2 antibody suppresses the normal-to-tumor vascular transition in the glioblastoma invasion zone. Experimental & molecular medicine 55 (2) (2023)
Eunhyeong Lee, Eun-Ah Lee, Eunji Kong, Haemin Chon, Melissa Llaiqui-Condori, Cheon Ho Park, Beom Yong Park, Nu Ri Kang, Jin-San Yoo, Hyun-Soo Lee, Hyung-Seok Kim, Sung-Hong Park, Seung-Won Choi, Dietmar Vestweber, Jeong Ho Lee, Pilhan Kim, Weon Sup Lee, Injune Kim
An agonistic anti-Tie2 antibody suppresses the normal-to-tumor vascular transition in the glioblastoma invasion zone. Experimental & molecular medicine (2023)
Eunhyeong Lee, Eun-Ah Lee, Eunji Kong, Haemin Chon, Melissa Llaiqui-Condori, Cheon Ho Park, Beom Yong Park, Nu Ri Kang, Jin-San Yoo, Hyun-Soo Lee, Hyung-Seok Kim, Sung-Hong Park, Seung-Won Choi, Dietmar Vestweber, Jeong Ho Lee, Pilhan Kim, Weon Sup Lee, Injune Kim
An agonistic anti-Tie2 antibody suppresses the normal-to-tumor vascular transition in the glioblastoma invasion zone. Experimental & molecular medicine 55 (2) (2023)
Eunhyeong Lee, Eun-Ah Lee, Eunji Kong, Haemin Chon, Melissa Llaiqui-Condori, Cheon Ho Park, Beom Yong Park, Nu Ri Kang, Jin-San Yoo, Hyun-Soo Lee, Hyung-Seok Kim, Sung-Hong Park, Seung-Won Choi, Dietmar Vestweber, Jeong Ho Lee, Pilhan Kim, Weon Sup Lee, Injune Kim
An agonistic anti-Tie2 antibody suppresses the normal-to-tumor vascular transition in the glioblastoma invasion zone. Experimental & molecular medicine 55 (2) (2023)
Seung-Won Choi, Hyun Ae Jung, Hee-Jin Cho, Tae Min Kim, Chul-Kee Park, Do-Hyun Nam, Se-Hoon Lee
A multicenter, phase II trial of GC1118, a novel anti-EGFR antibody, for recurrent glioblastoma patients with EGFR amplification. Cancer medicine (2023)
Seung-Won Choi, Yeri Lee, Kayoung Shin, Harim Koo, Donggeon Kim, Jason K Sa, Hee Jin Cho, Hye-Mi Shin, Se Jeong Lee, Hyunho Kim, Seok Chung, Jihye Shin, Cheolju Lee, Do-Hyun Nam
Mutation-specific non-canonical pathway of PTEN as a distinct therapeutic target for glioblastoma. Cell death & disease 12 (4) (2021)
Seung-Won Choi, Hyemi Shin, Jason K Sa, Hee Jin Cho, Harim Koo, Doo-Sik Kong, Ho Jun Seol, Do-Hyun Nam
Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma. Cancer medicine 7 (5) (2018)
Jin-Ku Lee, Zhaoqi Liu, Jason K Sa, Sang Shin, Ji-Guang Wang, Mykola Bordyuh, Hee Jin Cho, Oliver Elliott, Timothy Chu, Seung-Won Choi, Daniel I S Rosenbloom, In-Hee Lee, Yong Jae Shin, Hyun Ju Kang, Donggeon Kim, Sun Young Kim, Moon-Hee Sim, Jusun Kim, Taehyang Lee, Yun Jee Seo, Hyemi Shin, Mijeong Lee, Sung Heon Kim, Yong-Jun Kwon, Jeong-Woo Oh, Minsuk Song, Misuk Kim, Doo-Sik Kong, Jung Won Choi, Ho Jun Seol, Jung-Il Lee, Seung Tae Kim, Joon Oh Park, Kyoung-Mee Kim, Sang-Yong Song, Jeong-Won Lee, Hee-Cheol Kim, Jeong Eon Lee, Min Gew Choi, Sung Wook Seo, Young Mog Shim, Jae Ill Zo, Byong Chang Jeong, Yeup Yoon, Gyu Ha Ryu, Nayoung K D Kim, Joon Seol Bae, Woong-Yang Park, Jeongwu Lee, Roel G W Verhaak, Antonio Iavarone, Jeeyun Lee, Raul Rabadan, Do-Hyun Nam
Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nature genetics 50 (10) (2018)

Seung-Won Choi.css-eqlu8i{font-size:small;padding-left:4px;} (Seung Won Choi)

Publication Activity (10 Years)

Top Topics

Top Venues

Seung-Won Choi (Seung Won Choi)